Cargando…
Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe
Background. Many new cancer medicines have been developed that can improve patients’ outcomes. However, access to these agents comes later in Europe than in the United States (US). The aim of this study is to assess the access in Europe to newly registered cancer drugs and to get more insight in the...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464890/ https://www.ncbi.nlm.nih.gov/pubmed/32824444 http://dx.doi.org/10.3390/cancers12082313 |